The purpose of this study is to evaluate the effect of mild, moderate, or severe renal impairment, or end-stage renal disease (ESRD) requiring hemodialysis (HD), on the safety and tolerability of 1 or 2 single doses of sotagliflozin compared with healthy, demographically-matched subjects with normal renal function.

Inclusion Criteria:

• Adult male and female subjects ≥18 to ≤75 years of age
• Body mass index ≥18.0 to ≤36.0 kg/m2, at Screening
• Subjects with mild, moderate, or severe renal impairment, or ESRD requiring HD
• Control group of matched healthy subjects
• Willing and able to provide written informed consent

Exclusion Criteria:

• Presence of clinically significant physical, laboratory, or ECG findings that may interfere with any aspect of study conduct or interpretation of results
• Existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of sotagliflozin
• History of any major surgery within 6 months
• History of hepatic disease, or significantly abnormal liver function test
• Women who are breastfeeding or are planning to become pregnant during the study